Evaluation of Leucettinib-21 Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects, Down Syndrome, and Alzheimer's Disease Patients

The primary objective of this study is to evaluate the **safety** and **tolerability** of Leucettinib-21 in healthy male subjects, individuals with Down Syndrome, and patients with Alzheimer's disease. This is a critical assessment as it determines the potential risks and adverse effects associated with the administration of Leucettinib-21, which is essential for ensuring patient safety and guiding dosage recommendations in future clinical applications. The study also aims to investigate the **pharmacokinetics** and **pharmacodynamics** of Leucettinib-21, providing insights into the drug's absorption, distribution, metabolism, and excretion, as well as its biological effects and mechanism of action. These evaluations are crucial for understanding the drug's efficacy and optimizing its therapeutic use in the target populations.

The clinical trial involves a study population comprising **healthy male subjects** and individuals with **Down Syndrome** and **Alzheimer's disease**. The age range of participants spans from young adults to older adults. The trial exclusively includes male participants, as female subjects are not part of the study. The trial population was selected to include a vulnerable population, which is significant given the inclusion of individuals with Down Syndrome and Alzheimer's disease. However, the sponsor has not provided information regarding the total number of participants. The study does not specify any particular lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is a **Phase 1**, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Leucettinib-21. The trial will initially involve healthy male subjects receiving single and multiple ascending doses, followed by an open single dose administered to individuals with **Down Syndrome** and patients with **Alzheimer's disease**. The study is structured to assess the effects of food on the pharmacokinetics of Leucettinib-21. The estimated recruitment start date is November 15, 2023, with an anticipated completion date of October 31, 2024.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The trial will include multiple follow-up visits to monitor safety, collect pharmacokinetic and pharmacodynamic data, and assess tolerability. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather comprehensive data.

The expected duration of participant involvement will vary depending on the cohort assignment, with healthy subjects participating in the ascending dose phase and individuals with Down Syndrome and Alzheimer's disease participating in the open single-dose phase. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is designed to ensure rigorous data collection while prioritizing participant safety throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and preliminary efficacy. Although specific efficacy parameters or endpoints are not detailed, Phase 1 trials often involve the collection of data related to pharmacokinetics and pharmacodynamics, which may include biomarker levels or other relevant measures. The trial is scheduled to commence recruitment on November 15, 2023, with an estimated completion date of October 31, 2024. The methods and schedule for measuring, collecting, and analyzing efficacy parameters are not specified, but such trials generally employ validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The absence of detailed endpoints suggests that the trial may focus on exploratory outcomes to inform future studies.